A case series of SARS-CoV-2 reinfections caused by the variant of concern Gamma in Brazil

Authors

Felipe Gomes Naveca¹, Valdinete Alves Nascimento¹, Fernanda Nascimento¹, Maria Ogrzewalska², Alex Pauvolid-Corrêa^{2,3}, Mia Ferreira Araujo², Ighor Arantes^{2,4}, Érika Lopes Rocha Batista⁵, Alessandro Leonardo Álvares Magalhães⁵, Fernando Vinhal⁶, Tirza Peixoto Mattos⁷, Irina Riediger⁸, Maria do Carmo Debur⁸, Beatriz Grinsztejn⁹, Valdiléa G Veloso⁹, Patricia Brasil⁹, Rodrigo Ribeiro Rodrigues¹⁰, Darcita Buerger Rovaris¹¹, Sandra Bianchini Fernandes¹¹, Cristiano Fernandes¹², João Hugo Abdalla Santos¹³, Lígia Fernandes Abdalla¹⁴, Rubens Costa-Filho¹⁵, Marineide Silva⁷, Victor Souza¹, Ágatha Araújo Costa¹, Matilde Mejía¹, Maria Júlia Brandão¹, Luciana Fé Gonçalves¹, George Allan Silva¹, Michele Silva de Jesus¹, Karina Pessoa¹, André de Lima Guerra Corado¹, Debora Camila Gomes Duarte¹, Ana Beatriz Machado², Ketiuze de Azevedo Zukeram², Natalia Valente², Renata Serrano Lopes², Elisa Cavalcante Pereira², Luciana Reis Appolinario², Alice Sampaio Rocha², Luis Fernando Lopez Tort^{2,16}, Tsuyoshi Sekizuka¹⁷, Kentaro Itokawa¹⁷, Masanori Hashino¹⁷, Makoto Kuroda¹⁷, Gabriel Luz Wallau¹⁸, Edson Delatorre¹⁹, Tiago Gräf²⁰, Marilda Mendonça Siqueira², Gonzalo Bello⁴, Paola Cristina Resende²

1. Laboratório de Ecologia de Doenças Transmissíveis na Amazônia, Instituto Leônidas e Maria Deane, Fiocruz, Manaus, Brazil
2. Laboratory of Respiratory Viruses and Measles, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, RJ, Brazil
3. Department of Veterinary Integrative Biosciences, Texas A&M University, College Station, Texas, United States
4. Laboratório de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, Brazil
5. Secretaria de Saúde de Aparecida de Goiânia, Goiás, Brazil
6. Laboratório HLAGYN, Goiânia, Goiás, Brazil
7. Laboratório Central de Saúde Pública do Amazonas (LACEN-AM) Manaus, Amazonas, Brazil
8. Laboratório Central de Saúde Pública de Paraná (LACEN-PR) Curitiba, Paraná, Brazil
9. Instituto Nacional de Infectologia Evandro Chagas (INI), Fiocruz, Rio de Janeiro, Brazil
10. Laboratório Central de Saúde Pública do Espírito Santo (LACEN-ES), Vitória, Espírito Santo, Brazil
11. Laboratório Central de Saúde Pública do Estado de Santa Catarina (LACEN-SC), Florianópolis, Santa Catarina, Brazil
12. Fundação de Vigilância em Saúde do Amazonas - Dra Rosemary Costa Pinto, Manaus, Amazonas, Brazil
13. Hospital Adventista de Manaus, Manaus, Amazonas, Brazil
14. Universidade do Estado do Amazonas, Manaus, Brazil
15. Hospital Pró-cardíaco - Rede Américas UHG
16. CENUR Litoral Norte, Universidad de la República, Salto, Uruguay
17. Pathogen Genomics Center, National Institute of Infectious Diseases 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan
18. Instituto Aggeu Magalhães, Fundação Oswaldo Cruz, Recife, Pernambuco, Brazil
19. Departamento de Biologia Centro de Ciências Exatas, Naturais e da Saúde, Universidade Federal do Espírito Santo, Alegre, Brazil
20. Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Summary

The rapid spread of the SARS-CoV-2 Variant of Concern (VOC) Gamma during late 2020 and early 2021 in Brazilian settings with high seroprevalence raised some concern about the potential role of reinfections in driving the epidemic. Very few cases of reinfection associated with the VOC Gamma, however, have been reported. Here we describe 25 cases of SARS-CoV-2 reinfection confirmed by real-time RT-PCR twice within months apart in Brazil. SARS-CoV-2 genomic analysis confirmed that individuals were primo-infected between March and December 2020 with distinct viral lineages, including B.1.1, B.1.1.28, B.1.1.33, B.1.195 and P.2, and then reinfected with the VOC Gamma between 3 to 12 months after primo-infection. The overall mean cycle threshold (Ct) value of the first (25.7) and second (24.5) episodes were roughly similar for the whole group and 14 individuals displayed mean Ct values < 25.0 at reinfection. Sera of 14 patients tested by plaque reduction neutralization test after reinfection displayed detectable neutralizing antibodies against Gamma and other SARS-CoV-2 variants (B.1.33, B.1.1.28 and Delta). All individuals have milder or no symptoms after reinfection and none required hospitalization. The present study demonstrates that the VOC Gamma was associated with reinfections during the second Brazilian epidemic wave in 2021 and raised concern about the potential infectiousness of reinfected subjects. Although individuals here analyzed failed to mount a long-term sterilizing immunity, they developed a high anti-Gamma neutralizing antibody response after reinfection that may provide some protection against severe disease.

Keywords: COVID-19; SARS-CoV-2; reinfection; Variant of Concern; Gamma; P.1; Brazil.

Introduction

Cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection are a concerning topic for the coronavirus disease 2019 (COVID-19) response worldwide as they have implications for the long-term protective immunity induced by natural infections or by vaccines. Several cases of reinfection with distinct variants of SARS-CoV-2 have been reported¹, but it is unclear if these reinfection cases were the consequence of a limited immunity induced by the primo-infection or reflect the reinfecting virus's ability to evade the previous immune responses. The state of Amazonas, located in the north region of Brazil, was severely hit by a second wave of COVID-19 epidemic between December 2020 and March 2021 despite the high (>70%)² or relatively high (30-35%)³ estimated seroprevalence

at late 2020. This was associated with the emergence and spread of the Variant of Concern (VOC) Gamma which raised some concern about the potential role of reinfections in driving the second COVID-19 wave in the Amazonas⁴.

Gamma is one of the four SARS-CoV-2 VOCs currently recognized in the world⁵. All VOCs carry several mutations in the receptor-binding domain (RBD) of the spike (S) protein that reduce antibody neutralization and/or increase affinity for ACE2 receptor⁶⁻¹⁰, and may thus enhance the probability of reinfection. Some cases of reinfection with VOCs have been described worldwide¹¹⁻¹⁸, but the precise frequency of those events remains unclear. A study conducted in the United Kingdom (UK) identified possible reinfections in 0.7% (95% CI 0.6-0.8%) of individuals infected during September-December 2020 and found no evidence that the frequency of reinfections was higher for the VOC Alpha than for pre-existing non-VOCs¹⁹. In Brazil, previous studies documented a few cases of reinfection with lineages B.1.1.28, B.1.1.33 and B.1.2²⁰⁻²², with lineage P.2 that harbors the mutation S: E484K^{23,24} and with the VOC Gamma^{17,18}. However, there is no evidence that reinfections with Gamma were more frequent than with non-VOCs.

In this study, we report a series of 25 cases of reinfections with the VOC Gamma in subjects from six different Brazilian states who had been primo-infected with different non-VOC SARS-CoV-2 lineages between 3 to 12 months earlier. The large number of SARS-CoV-2 reinfections with the VOC Gamma here described demonstrate that this viral variant is able to infect recovered individuals and suggests that this event was not a rare phenomenon in Brazil.

Methods

Case series and ethical aspects. In this study we include 25 cases of adults living at four different regions of Brazil, including West-Central (n=13), South (n=7), North (n=3) and Southeast (n=2) that presented two episodes of COVID-19 with at least 90 days apart. The first and second episodes occurred between March and December 2020 and between December 2020 and June 2021, respectively. All patients had nasopharyngeal and oropharyngeal swabs (NPS) collected in viral transport media (VTM) and tested by SARS-CoV-2 real time RT-PCR in their respective State Health Departments as part of the official network of the Brazilian Ministry of Health for the diagnostic and surveillance of SARS-CoV-2. Samples of patients who were SARS-COV-2 positive by real time RT-PCR twice with at least 90 days apart, according to the Technical Note 52/2020-CGPNI/DEIDT/SVS/MS²⁵, were sent to the National Reference Laboratory for reinfection

investigation and confirmation. This study was approved by the Ethics Committee of the Amazonas State University (CAAE: 25430719.6.0000.5016) and by the Ethics Committee of the FIOCRUZ (CAAE: 68118417.6.0000.5248).

SARS-CoV-2 real time RT-PCR confirmation and genomic sequencing. After the detection of two SARS-CoV-2 positive samples by real time RT-PCR from the same patient the samples were accessed and sent to one of the sequencing hubs of the COVID-19 Fiocruz Genomic Surveillance Network (LVRS, Fiocruz, Rio de Janeiro; ILMD, Fiocruz Amazonas; or HLAGyn, Goiás) to have the total nucleic acid extracted from the VTM specimens by Maxwell® RSC Viral Total Nucleic Acid Purification Kit (Promega, Madison, WI) or QIAmp RNA viral mini kit (Qiagen). Then, immediately submitted to a real-time RT-PCR designed to amplify gene N of SARS-CoV-2²⁶ or EDx kit Biomanguinhos protocol to amplify the gene E²⁷. Using the nucleic acid extracts, we generated the whole genome of SARS-CoV-2 by the in-house amplicon sequencing protocols described^{28,29} but with some improvements in the primer scheme (**Supplementary file**) or by the Illumina COVIDSeq test kit (Illumina) with some adaptations³⁰. Libraries were produced with Nextera XT and sequenced with MiSeq Reagent Micro Kit v2 (300-cycles). The FASTQ reads were obtained following the Illumina pipeline on BaseSpace, imported into Geneious v10.2.6, trimmed (BBduk 37.25) or into CLC Genomic Workbench (Qiagen), and mapped (BBMap 37.25) against the reference sequence EPI_ISL_402124 available in EpiCoV database from GISAID (<https://www.gisaid.org/>). Consensus sequences with a mean read depth of 1,341x were generated after excluding duplicate reads.

Genomic analyses. PANGO lineages were assigned to all sequences by the Pangolin algorithm³¹, and later confirmed using maximum likelihood (ML) phylogenetic analyses. SARS-CoV-2 complete genome sequences from all cases were aligned with high quality (<1% of N) SARS-CoV-2 whole-genomes (>29 kb) of representative lineages retrieved from EpiCoV database at GISAID. The final dataset of each variant to which primoinfection and reinfection sequences were previously assigned were obtained by clusterization of their GISAID complete datasets using CD-HIT v.4.8.1³¹. The resulting dataset was aligned by MAFFT v7.467³² and subjected to a maximum likelihood (ML) phylogenetic analysis with IQ-TREE v2.1.2³³ under the best nucleotide substitution model selected by the ModelFinder application³⁴. The branch support was assessed by the approximate likelihood-ratio test based on the Shimodaira–Hasegawa-like procedure (SH-aLRT) with 1,000 replicates³⁵.

Serological analyses. A total of 14 serum samples collected from 12 to 70 days after the second episode of COVID-19 were tested for SARS-CoV-2-specific neutralizing antibodies

(NAb) by plaque reduction neutralization test (PRNT₉₀). We also include serum samples from two control groups: 1) samples collected 3 to 21 days after hospitalization from 30 individuals primo-infected with the Gamma variant and 2) samples collected from 10 individuals with hybrid immunity acquired by fully vaccination after infection with a non-VOC variant (n = 5) or by infection with the Gamma variant after vaccination. For PRNT₉₀, an aliquot of serum sample inactivated at 56°C for 30 minutes was tested in VERO CCL-81 cells in duplicate at serial two-fold dilutions to determine 90% endpoint titers against four infectious SARS-CoV-2 lineages, including the LVRS reference strains B.1.1.33 (EPI_ISL_1181439), B.1.1.28 (EPI_ISL_2645638), Gamma (EPI_ISL_1402431) and Delta (EPI_ISL_2645417). Serum samples were considered seropositive when a serum dilution of at least 1:10 reduced no less than 90% of the formation of SARS-CoV-2 viral plaques³⁶.

Statistical analyses. The non-parametric Wilcoxon matched-pairs signed rank test was used to compare multiple samples per subject (real time RT-PCR cycle threshold [Ct] of samples from the first and second episodes and level of NAb against different SARS-CoV-2 variants in the plasma taken after reinfection) and the Mann-Whitney test was used to compare samples from different groups of individuals. Only Ct values from samples analyzed with the same real time RT-PCR diagnostic assay were compared. Specimens in which NAb could not be detected (PRNT₉₀ <10) were assigned an arbitrary value of five in order to include NAb as a continuous variable. The threshold for statistical significance was set to $P < 0.05$. Graphics and statistical analyses were performed using GraphPad v9.02 (Prism Software, United States).

Results

We analyzed 25 individuals that presented two episodes of COVID-19 within an interval of 3 to 12 months period (**Table 1, Figure S1**). They were predominantly female (64%), unvaccinated (92%) and with an age that ranged from 17 to 73 years old. Most cases had no reported comorbidities (80%) and presented mild clinical symptoms (92%) including fever, myalgia, cough, sore throat, nausea, anosmia, ageusia, and back pain in the first episode of COVID-19. Two individuals required hospitalization at primo-infection. Patients had milder clinical presentation (84%) or were asymptomatic (16%) during the second infection. All samples tested were positive to SARS-CoV-2 by real time RT-PCR with a Ct value ranging from 18.0 to 34.3. The overall mean Ct value of the first (25.7) and second (24.5) episodes were not significantly different ($P > 0.05$) for the whole group (**Fig 1A**). Of note, 14 individuals displayed mean Ct values < 25.0 during the second episode of COVID-19 and nine individuals displayed much lower Ct values in the second than in the first episode

($Ct_{\text{first}} - Ct_{\text{second}} > 3.0$). The overall mean between onset symptoms and collection date were 4 days in the first infection and 3.5 in the reinfection (**Table 1**).

Whole SARS-CoV-2 genomes were recovered from all 50 samples analyzed. Most of them were high quality sequences (<1% of N) with a few exceptions (<15% of N) that were recovered from samples with low viral load ($Ct > 33$), limit Ct value for sequencing procedure. All SARS-CoV-2 genomes recovered contained enough SNP markers to confidently assign the corresponding SARS-CoV-2 lineage with high support (1.0). The PANGO lineage system indicated the presence of five different SARS-CoV-2 lineages in the first COVID-19 episodes (B.1.1, B.1.1.28, B.1.1.33, B.1.195, B.1.1.198 and P.2) and the unique presence of the VOC Gamma (lineage P.1) and Gamma plus (lineages P.1.2, P.1.7, P.1.12 and P.1.14) in all second episodes (**Table 1**). The ML phylogenetic analysis confirmed the initial lineage assignment on the majority of cases (**Fig S2 A and B**). A single divergence (EPI_ISL_1114151, Patient 2) was detected in a genome with a significant number of unidentified positions (14%) that could potentially lead to ambiguity in its classification. This allowed us to conclude that all suspected cases correspond to reinfections with the VOC Gamma. Analysis of the Spike (S) gene of Gamma viruses detected at reinfection reveals the presence of the canonical lineage signatures plus additional mutations L5F and T76I in one P.1 sequence, D178G in one P.1.12 sequence, A522V in one P.1 sequence and P681H in two P.1.7 sequences (**Table S1, Figure S2 C**).

Serum samples of 14 patients collected 10-75 days after the second SARS-CoV-2 positive real time RT-PCR were tested for plaque reduction neutralization against B.1.1.28, B.1.1.33, Gamma and Delta variants. Selected individuals were primo-infected with lineages B.1.1 ($n = 3$), B.1.1.28 ($n = 4$), B.1.1.33 ($n = 5$), B.1.195 ($n = 1$), and P.2 ($n = 1$). Most patients (86%) have detectable NAb against all viral lineages tested, although the neutralization geometric mean titer against Delta ($PRNT_{90} = 49$) was significantly lower ($P < 0.05$) than for B.1.1.28 ($PRNT_{90} = 103$), B.1.1.33 ($PRNT_{90} = 160$) and Gamma ($PRNT_{90} = 160$) (**Fig 1B and Table 1**). The levels of Nab in reinfected subjects were next compared with a group of 30 hospitalized individuals that were primo-infected with variant Gamma and 10 individuals with hybrid immunity that were either primo-infected with a non-VOC variant and then fully vaccinated ($n = 5$) or infected with the variant Gamma after vaccination ($n = 5$, breakthrough cases). The three groups displayed similar levels of NAb against Gamma ($P > 0.05$), but levels against Delta in reinfected and in individuals with hybrid immunity were significantly higher ($P < 0.0003$) than in hospitalized individuals primo-infected with Gamma (**Fig 1C**).

Discussion

This study describes 25 individuals from Brazil that were primo-infected with SARS-CoV-2 lineages B.1.195 (two cases), B.1.1 (two cases), B.1.1.28 (eight cases), B.1.1.33 (11 cases), B.1.1.198 (one case) and P.2 (one case) between March and December 2020 and reinfected with the VOC Gamma 3-12 months later (between December 2020 and June 2021). Lineages B.1.1.28 and B.1.1.33 were the most prevalent Brazilian variants between March and October 2020, lineage B.1.195 was locally prevalent in the Amazonas state from March to June 2020, lineage B.1.1 circulates at low prevalence in Brazil during 2020, lineage P.2 was highly prevalent in most Brazilian states between November 2020 and February 2021 and the VOC Gamma was frequently detected in the Amazonas state since December 2020 and became the most prevalent viral variant across all Brazilian regions from February to July 2021 (<http://www.genomahcov.fiocruz.br/dashboard/>). Thus, the viruses detected at primo-infection and reinfection in our study reflect the most prevalent contemporaneous SARS-CoV-2 variants circulating in Brazil at the time period.

These cases of reinfection as well as those previously reported for the variants P.2/Gamma in Brazil^{17,23,24} are consistent with the described capability of viruses carrying the substitution S:E484K to escape from anti-SARS-CoV-2 antibodies⁷⁻⁹ and to cause SARS-CoV-2 breakthrough infections in vaccinated persons³⁷⁻³⁹. These observations are also consistent with previous studies that showed that variant Gamma is more resistant to neutralization by sera from convalescent/vaccinated patients than ancestral Wuhan related strains⁴⁰⁻⁴⁵. It is possible that the absence of anti-SARS-CoV-2 antibodies against the S: K484 variant in subjects infected during 2020 may have facilitated reinfections with variants Gamma and P.2. The detection of one case of reinfection with Gamma following primo-infection with lineage P.2; however, supports the hypothesis that reinfection might have also occurred in spite of pre-existing anti-S: K484 antibodies. It is also possible that the large number of detected reinfection cases by the VOC Gamma here detected resulted from its high infectivity and transmissibility phenotype^{46,47}.

We may also speculate that mild severity of the first COVID-19 episode in patients here described induced a transient protective immunity, but anti-SARS-CoV-2 NAb substantially decayed by the time of reinfection⁴⁸⁻⁵¹. One previous study that provided estimates of the typical time period to reinfection for several coronaviruses, and predicted that reinfection with SARS-CoV-2 under endemic conditions would likely occur between 3 and 63 months after peak antibody response, with a median of 16 months⁵². Although we do not measure the anti-SARS-CoV-2 NAb levels before reinfections, all individuals in our

study were reinfected between 3 and 12 months after the primo-infections, a time-frame thus consistent with the hypothesis of waning humoral immunity. According to this model, reinfection will become increasingly common as the epidemic progresses, and this may also partially explain the much larger number of reinfections with variant Gamma here reported when compared with previous locally prevalent variants in Brazil.

There is limited evidence on the risk of SARS-CoV-2 transmission from reinfected individuals to susceptible contacts. Several studies demonstrated that Ct values that inversely correlate with the log viral load also negatively correlate with cultivable virus^{53,54} and the transmission risk^{55,56}. It was reported that up to 70% of patients remained positive in culture at a $Ct \leq 25$ ^{53,54} and that 85% of case-contact pairs with plausible onward transmission had a case $Ct < 25$ ^{55,56}, suggesting that a $Ct \leq 25$ could be used as a good surrogate of infectivity. Notably, our analyses revealed that samples taken at first and second infections displayed roughly similar mean Ct values (25.7 vs 24.5) and that 56% (14/25) of individuals displayed a mean Ct value < 25.0 at reinfection. These findings support that, individuals here analyzed display comparable viral loads in the upper respiratory tract at primo-infection and reinfection and that viral load at reinfection may have been sufficient for some patients to transmit the virus to others. Thus, reinfections with the VOC Gamma might have contributed to the onward transmission of SARS-CoV-2 in Brazil, although the precise frequency of those events remains unknown.

In the present study, the serum samples of 14 patients were collected between 10-75 days after the reinfection and all of them displayed detectable NAb against Gamma and also against the other three SARS-CoV-2 lineages tested (B.1.1.28, B.1.1.33 and Delta). It is also interesting to note that most patients here analyzed were young (< 50 years old), have no known underlying conditions and all of them have a benign clinical outcome during the second infection. These findings suggest that reinfections did not occur because of genetic immunological deficits in the individuals here analyzed and that partial immunity induced by early SARS-CoV-2 variants may have provided some protection against severe illness during reinfection with the variant Gamma⁵⁷. Furthermore, the Gamma reinfected subjects have similar levels of NAb against Gamma and Delta variants than a group of individuals with hybrid immunity (fully vaccination after infection or breakthrough cases) and higher levels against Delta than a group of subjects primo-infected with Gamma, supporting that reinfection may have boosted neutralizing titers against different viral variants as seen after vaccination of previously infected persons⁵⁸⁻⁶⁰.

Longitudinal analyses revealed that anti-SARS-CoV-2 IgG levels and *in vitro* NAb titers induced by natural infection correlate with protection against reinfection⁶¹⁻⁶⁴ but the precise level of NAb necessary for protection from infection and/or reinfection remains unclear⁶⁵. Of interest, sera from patients here collected 10-75 days after reinfection were less potent to neutralize the variant Delta, relative to the variant Gamma and other non-VOCs tested. This observation coincides with a recent study that revealed that sera from convalescents individuals infected with VOCs Beta and Gamma showed a mark reduction of ~11-fold in neutralization of Delta compared with the corresponding infecting VOCs⁶⁶ and with another study that points that SARS-CoV-2 variants can elicit polyclonal antibodies with different immunodominance hierarchies⁶⁷. Considering the recent and ongoing dissemination of variant Delta in Brazil and the progress of vaccination roll-out, it will be important to determine whether individuals primo-infected with Gamma that were vaccinated or not will be at risk of reinfection with Delta.

Our study has several limitations. First, although Ct values could be used as a surrogate of infectivity, we have no contact-tracing information to demonstrate that reinfected subjects were able to transmit the virus to susceptible individuals. Second, our study was limited by the absence of longitudinal data of anti-SARS-CoV-2 NAb, particularly between the first and the second COVID-19 episodes. Thus, we could not confirm if primo-infections effectively induce a transient neutralization response, we could not measure the level of NAb immediately before reinfections and no definitive conclusions could be drawn about the precise impact of reinfections on NAb titers.

In summary, these findings confirm that natural infection by SARS-CoV-2 do not necessarily prevent subsequent infections and further demonstrate that reinfection with the VOC Gamma in people who had a first symptomatic infection between 3 to 12 months earlier was not a rare phenomenon in Brazil. Although, reinfections cases were observed in individuals without comorbidities and with mild disease, no significant decrease in viral load, represented by Ct values, during reinfection was observed when compared with primo-infection. Further studies are necessary to determine whether reinfection with Gamma and other VOCs is a widespread phenomenon and to understand to what extent reinfection will contribute to the onward endemic transmission of SARS-CoV-2. Further work is also needed to understand how primary infections interfere with the clinical outcome of secondary infections and the degree of long-term sterilizing immunity acquired after reinfections.

Figure 1. Viral load in NSP samples and neutralization capacity of convalescent serum of reinfected individuals. **A)** Real time RT-PCR Ct value distribution of NSP SARS-CoV-2 positive samples taken from 25 individuals at primo-infection and reinfection. Each line represents a single individual. **B)** Individual trajectories of neutralization titers (PRNT_{90}) against different SARS-CoV-2 lineages in convalescent plasma from 14 individuals collected 10-75 days following SARS-CoV-2 reinfection. Each line represents a single individual. **C)** Comparison of neutralization titers (PRNT_{90}) against Gamma and Delta variants in convalescent plasma from three groups that included: 1) hospitalized individuals primo-infected with Gamma ($n = 30$; Gamma-PI), 2) individuals with hybrid immunity acquired by vaccination after infection or by infection after vaccination ($n = 10$; PI+VAC), and 3) individuals reinfected with Gamma ($n = 14$; Gamma-RI). Horizontal bars represent sample medians and interquartile range. Two-tailed P values calculated with the Wilcoxon matched-pairs signed rank test (A and B) or the Mann-Whitney test (C) are shown.

Table 1. Clinical and epidemiological details of Gamma reinfection cases.

Case	Age, Gender	Virus name	Acession number GISAID	Depth coverage	Pango Lineage	ct	Onset symptoms	Collection date	Clinical outcome 1st COVID-19 episode	Time between first and second infection	Vaccination
1	F	hCoV-19/Brazil/AM-FIOCRUZ-20140055FN-R1/2020	EPI_ISL_811148	3283x	B.1.195	27,5	03/2020	03/2020	Not hospitalized. Recovered.	281	no
		hCoV-19/Brazil/AM-FIOCRUZ-20143138FN-R2/2020	EPI_ISL_811149	4663X	P.1	20,5	12/2020	12/2020	Not hospitalized. Recovered.		
2	F	hCoV-19/Brazil/AM-FIOCRUZ-20142223MR-R1/2020	EPI_ISL_1114151	1333x	B.1.1	34	10/2020	10/2020	Not hospitalized. Recovered.	92	no
		hCoV-19/Brazil/AM-FIOCRUZ-21140415MR-R2/2021	EPI_ISL_1034304	6452x	P.1	19,7	01/2021	01/2021	Not hospitalized. Recovered.		
3	F	hCoV-19/Brazil/AM-FIOCRUZ-20140452MJ-R1/2020	EPI_ISL_1034305	1063x	B.1.195	19,9	04/2020	04/2020	Not hospitalized. Recovered.	282	no
		hCoV-19/Brazil/AM-FIOCRUZ-21140646MJ-R2/2021	EPI_ISL_1034306	2077x	P.1	21	asymptomatic	01/2021	Not hospitalized. Recovered.		
4	M	hCoV-19/Brazil/GO-HLAGYN-1031607-R1/2021	EPI_ISL_2017281	1679x	B.1.1.33	24,5	08/2020	08/2020	Not hospitalized. Recovered.	224	no
		hCoV-19/Brazil/GO-HLAGYN-1586463_R2/2021	EPI_ISL_2017282	888X	P.1	27,9	03/2021	03/2021	Not hospitalized. Recovered.		
5	F	hCoV-19/Brazil/GO-HLAGYN-1088252-R1/2021	EPI_ISL_2017323	826x	B.1.1	28,6	08/2020	09/2020	Not hospitalized. Recovered.	188	no
		hCoV-19/Brazil/GO-HLAGYN-1520715_R2/2021	EPI_ISL_2017324	764x	P.1	24	03/2021	03/2021	Not hospitalized. Recovered.		
6	F	hCoV-19/Brazil/GO-HLAGYN-855822-R1/2020	EPI_ISL_2017449	523x	B.1.1.33	31,7	07/2020	07/2020	Not hospitalized. Recovered.	291	Yes 1st 21/01/2021 2nd 26/02/2021
		hCoV-19/Brazil/GO-HLAGYN-1623988_R2/2021	EPI_ISL_2187985	1193X	P.1	30	04/2021	04/2021	Not hospitalized. Recovered.		
7	F	hCoV-19/Brazil/GO-HLAGYN-920573-R1/2020	EPI_ISL_2187989	815X	B.1.1.33	32,1	07/2020	07/2020	Not hospitalized. Recovered.	280	no
		hCoV-19/Brazil/GO-HLAGYN-1633028_R2/2021	EPI_ISL_2187990	925X	P.1	27,5	04/2021	04/2021	Not hospitalized. Recovered.		
8	F	hCoV-19/Brazil/GO-HLAGYN-1013302-R1/2020	EPI_ISL_2188000	1080X	B.1.1.33	23,4	08/2020	08/2020	Not hospitalized. Recovered.	262	no
		hCoV-19/Brazil/GO-HLAGYN-1638914_R2/2021	EPI_ISL_2227564	1171x	P.1	28,2	04/2021	05/2021	Not hospitalized. Recovered.		
9	M	hCoV-19/Brazil/PR-FIOCRUZ-34071-	EPI_ISL_2196362	601x	B.1.1.28	24,67	06/2020	06/2020	Hospitalized. Recovered.	286	no

		R1/2020									
		hCoV-19/Brazil/PR-FIOCRUZ-21069-R2/2021	EPI_ISL_2196252	348x	P.1	22,38	03/2021	03/2021	Not hospitalized. Recovered.		
10	F	hCoV-19/Brazil/PR-FIOCRUZ-33964-R1/2020	EPI_ISL_3061893	1584x	B.1.1.28	18,1	10/2020	10/2020	Not hospitalized. Recovered.	150	no
		hCoV-19/Brazil/PR-FIOCRUZ-16726-R2/2021	EPI_ISL_3061892	883x	P.1.14	21,14	asymptomatic	03/2021	Not hospitalized. Recovered.		
11	M	hCoV-19/Brazil/SC-FIOCRUZ-34264-R1/2020	EPI_ISL_4563059	711x	B.1.1.28	28,88	07/2020	07/2020	Not hospitalized. Recovered.	327	no
		hCoV-19/Brazil/SC-FIOCRUZ-33117-R2/2021	EPI_ISL_4563061	1885x	P.1	21,03	05/2021	06/2021	Not hospitalized. Recovered.		
12	M	hCoV-19/Brazil/SC-FIOCRUZ-33864-R1/2020	EPI_ISL_3061901	1217x	B.1.1.28	23,34	09/2020	09/2020	Not hospitalized. Recovered.	162	no
		hCoV-19/Brazil/SC-FIOCRUZ-11195-R2/2021	EPI_ISL_1534003	1708x	P.1	21,81	02/2021	02/2021	Not hospitalized. Recovered.		
13	F	hCoV-19/Brazil/SC-FIOCRUZ-34078-R1/2020	EPI_ISL_2196357	1094x	B.1.1.28	21,97	09/2020	09/2020	Not hospitalized. Recovered.	192	no
		hCoV-19/Brazil/SC-FIOCRUZ-22230-R2/2021	EPI_ISL_2196249	3046x	P.1	20,03	04/2021	04/2021	Not hospitalized. Recovered.		
14	F	hCoV-19/Brazil/SC-FIOCRUZ-34070-R1/2020	EPI_ISL_2196360	297x	B.1.1.28	18,14	08/2020	08/2020	Not hospitalized. Recovered.	219	no
		hCoV-19/Brazil/SC-FIOCRUZ-20618-R2/2021	EPI_ISL_2196250	163x	P.1	25,79	03/2021	03/2021	Not hospitalized. Recovered.		
15	M	hCoV-19/Brazil/SC-FIOCRUZ-34157-R1/2020	EPI_ISL_3061902	639x	B.1.1.33	27,81	10/2020	10/2020	Not hospitalized. Recovered.	150	no
		hCoV-19/Brazil/SC-FIOCRUZ-25336-R2/2021	EPI_ISL_3061900	718x	P.1.2	17,95	03/2021	03/2021	Not hospitalized. Recovered.		
16	F	hCoV-19/Brazil/ES-FIOCRUZ-33961-R1/2020	EPI_ISL_3061879	5088x	B.1.1.33	19,38	12/2020	12/2020	Not hospitalized. Recovered.	93	Yes
		hCoV-19/Brazil/ES-FIOCRUZ-16403-R2/2021	EPI_ISL_2645521	1207x	P.1	24,5	03/2021	03/2021	Not hospitalized. Recovered.		1st 29/01/21 2nd 09/04/21
17	M	hCoV-19/Brazil/RJ-FIOCRUZ-1691-R1/2020	EPI_ISL_2196361	2480x	B.1.1.33	32,17	04/2020	04/2020	Not hospitalized. Recovered.	387	no
		hCoV-19/Brazil/RJ-FIOCRUZ-21373-R2/2021	EPI_ISL_2196251	2366x	P.1	18,3	not informed	04/2021	Not hospitalized. Recovered.		
18	F	hCoV-19/Brazil/GO-HLAGYN-826071_R1/2020	EPI_ISL_2497433	882X	B.1.1.33	20,04	06/2020	06/2020	Not hospitalized. Recovered.	320	no
		hCoV-19/Brazil/GO-HLAGYN-1651296_R2/2021	EPI_ISL_2497440	586X	P.1	31,3	asymptomatic	05/2021	Not hospitalized. Recovered.		

19	F	hCoV-19/Brazil/GO-HLAGYN-870588_R1/2020	EPI_ISL_2497434	834X	B.1.1.28	23,75	07/2020	07/2020	Not hospitalized. Recovered.	323	no
		hCoV-19/Brazil/GO-HLAGYN-1680829_R2/2021	EPI_ISL_2497469	900X	P.1	29,43	asymptomatic	05/2021	Not hospitalized. Recovered.		
20	F	hCoV-19/Brazil/GO-HLAGYN-977307_R1/2020	EPI_ISL_2497435	792X	B.1.1.33	26,58	07/2020	08/2020	Not hospitalized. Recovered.	292	no
		hCoV-19/Brazil/GO-HLAGYN-1673804_R2/2021	EPI_ISL_2497459	856X	P.1.7	32,86	05/2021	05/2021	Not hospitalized. Recovered.		
21	M	hCoV-19/Brazil/GO-HLAGYN-1216505_R1/2020	EPI_ISL_2617626	1004X	B.1.1.28	23,96	10/2020	10/2020	Hospitalized. Recovered.	223	no
		hCoV-19/Brazil/GO-HLAGYN-1676036_R2/2021	EPI_ISL_2617627	754X	P.1	26,41	05/2021	05/2021	Not hospitalized. Recovered.		
22	F	hCoV-19/Brazil/GO-HLAGYN-998600_R1/2020	EPI_ISL_2921603	173x	B.1.1.33	27,04	08/2020	08/2020	Not hospitalized. Recovered.	300	no
		hCoV-19/Brazil/GO-HLAGYN-1700566_R2/2021	EPI_ISL_2921604	573x	P.1	20,92	06/2021	06/2021	Not hospitalized. Recovered.		
23	M	hCoV-19/Brazil/GO-HLAGYN-1123866_R1/2020	EPI_ISL_2921605	931x	B.1.1.33	22,44	09/2020	09/2020	Not hospitalized. Recovered.	266	no
		hCoV-19/Brazil/GO-HLAGYN-1696639_R2/2021	EPI_ISL_2921606	935x	P.1	27,89	06/2021	06/2021	Not hospitalized. Recovered.		
24	F	hCoV-19/Brazil/GO-HLAGYN-1074287_R1/2020	EPI_ISL_3087898	869X	B.1.1.198	27,65	08/2020	08/2020	Not hospitalized. Recovered.	290	no
		hCoV-19/Brazil/GO-HLAGYN-1715778_R2/2021	EPI_ISL_2921607	837x	P.1.7	29,59	06/2021	06/2021	Not hospitalized. Recovered.		
25	M	hCoV-19/Brazil/GO-HLAGYN-1330226_R1/2020	EPI_ISL_2921608	750x	P.2	34,29	12/2020	12/2020	Not hospitalized. Recovered.	182	no
		hCoV-19/Brazil/GO-HLAGYN-1724317_R2/2021	EPI_ISL_2921609	620x	P.1	21,47	06/2021	06/2021	Not hospitalized. Recovered.		

Role of the funding source. The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report and in the decision to submit the paper for publication. All authors confirm that they had full access to all the data in the study and accept responsibility to submit for publication.

Contributors

FGN, AAM and MMS obtaining financial support. FGN, MMO, APC, IIA, GGB and PCR contributed to data analysis and writing of the manuscript. AAM, ERB, TPM, IIR, MCD, BBG, VGV, PPB, RRR, DBR, SBF, CCF, JAS, LFA and RCF contributed to patient and public health surveillance data. AAC, AGC, ASR, DBR, DGD, ECP, FFV, FGN, FN, GAS, IIR, KAZ, KKP, LFG, LRA, MCD, MJB, MMM, MMO, MMS, MSJ, PCR, RRR, RSL, SBF, TPM, VAN and VVS contributed to diagnostics and genomic sequencing. ABM, APC, LLT, MFA and NNV contributed to viral isolation and neutralization analyses. EED, GGB, GLW, IIA and TTG performed the phylogenetic analysis. TS, KI, MH, and MK contributed with editing of the manuscript and sharing previously unpublished data. All authors read and accept the participation in this manuscript.

Declaration of interests

All authors declare no competing interests.

Data sharing

The consensus SARS-CoV-2 sequences generated in this work are available online at EpiCoV database in GISAID <https://www.gisaid.org> under the accession numbers: EPI_ISL_811148, EPI_ISL_811149, EPI_ISL_1034304 to 1034306, EPI_ISL_1114151, EPI_ISL_1534003, EPI_ISL_2017281 to 2017324, EPI_ISL_2017449, EPI_ISL_2187985, EPI_ISL_2187989, EPI_ISL_2187990, EPI_ISL_2188000, EPI_ISL_2196249 to 2196252, EPI_ISL_2196357, EPI_ISL_2196360 to 2196362, EPI_ISL_2227564, EPI_ISL_2497433 to 2497435, EPI_ISL_2497440, EPI_ISL_2497459, EPI_ISL_2497469, EPI_ISL_2617626, EPI_ISL_2617627, EPI_ISL_2645521, EPI_ISL_2921603 to 2921609, EPI_ISL_3061879, EPI_ISL_3061892, EPI_ISL_3061893, EPI_ISL_3061900 to 3061902, EPI_ISL_3087898, EPI_ISL_4563059 and EPI_ISL_4563061.

Funding

Funding support from Department of Science and Technology (DECIT), Ministry of Health (MoH), CGLab/MoH (General Laboratories Coordination of Brazilian Ministry of Health), CVSLR/FIOCRUZ (Coordination of Health Surveillance and Reference Laboratories of Oswaldo Cruz Foundation), CNPq COVID-19 MCTI 402457/2020-0 and 403276/2020-9; INOVA Fiocruz VPPCB-005-FIO-20-2 and VPPCB-007-FIO-18-2-30; FAPERJ: E26/210.196/2020; FAPEAM (PCTI-EmergeSaude/AM call 005/2020 and Rede Genômica de Vigilância em Saúde - REGESAM). This study was also supported by a Grant-in Aid from the Japan Agency for Medical Research and Development (AMED) under Grant number JP20fk0108103.

Acknowledgments

We would like to thank all Genomic Coronavirus Fiocruz Network members (<http://www.genomahcov.fiocruz.br/>), the Multi-user Research Facility of Biosafety Level 3 Platform of the Oswaldo Cruz Institute (IOC), Fiocruz, and the CGLab/MoH and Secretary of Surveillance and Health of the Brazilian MoH (SVS-MS). Additionally, we gratefully acknowledge the Authors from the originating laboratories responsible for obtaining the

specimens and the submitting laboratories where genetic sequence data were generated and shared via the GISAID, on which this research is based (**Supplementary Table 1**).

References

- 1 Babiker, A., Marvil, C., Waggoner, J. J., Collins, M. & Piantadosi, A. The Importance and Challenges of Identifying SARS-CoV-2 Reinfections. *J Clin Microbiol*, doi:10.1128/JCM.02769-20 (2020).
- 2 Buss, L. F. *et al.* Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic. *Science* **371**, 288-292, doi:10.1126/science.abe9728 (2021).
- 3 He, D. *et al.* The unexpected dynamics of COVID-19 in Manaus, Brazil: Was herd immunity achieved? *medRxiv* (2021).
<<https://doi.org/10.1101/2021.02.18.21251809>>.
- 4 Sabino, E. C. *et al.* Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. *Lancet* **397**, 452-455, doi:10.1016/S0140-6736(21)00183-5 (2021).
- 5 World Health Organization. *Tracking SARS-CoV-2 variants*,
<<https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/>> (2021).
- 6 Tegally, H. *et al.* Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. *medRxiv*, doi:10.1101/2020.12.21.20248640 (2020).
- 7 Weisblum, Y. *et al.* Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. *Elife* **9**, doi:10.7554/eLife.61312 (2020).
- 8 Greaney, A. J. *et al.* Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. *Cell Host Microbe*, doi:10.1016/j.chom.2021.02.003 (2021).
- 9 Baum, A. *et al.* Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. *Science* **369**, 1014-1018, doi:10.1126/science.abd0831 (2020).
- 10 Rambaut, A. *et al.* Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. *Virological.org* (2020).
<<https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563>>.
- 11 Harrington, D. *et al.* Confirmed Reinfection with SARS-CoV-2 Variant VOC-202012/01. *Clin Infect Dis*, doi:10.1093/cid/ciab014 (2021).
- 12 Koopsen, J. *et al.* Rapid reinfection with SARS-CoV-2 variant-of-concern Alpha detected in a nurse during an outbreak at a non-covid inpatient ward: lessons learned. *Antimicrob Resist Infect Control* **10**, 137, doi:10.1186/s13756-021-01008-4 (2021).
- 13 Shastri, J. *et al.* Severe SARS-CoV-2 Breakthrough Reinfection With Delta Variant After Recovery From Breakthrough Infection by Alpha Variant in a Fully Vaccinated Health Worker. *Front Med (Lausanne)* **8**, 737007, doi:10.3389/fmed.2021.737007 (2021).
- 14 Novazzi, F. *et al.* SARS-CoV-2 B.1.1.7 reinfection after previous COVID-19 in two immunocompetent Italian patients. *J Med Virol* **93**, 5648-5649, doi:10.1002/jmv.27066 (2021).
- 15 Staub, T. *et al.* Case series of four re-infections with a SARS-CoV-2 B.1.351 variant, Luxembourg, February 2021. *Euro Surveill* **26**, doi:10.2807/1560-7917.ES.2021.26.18.2100423 (2021).
- 16 Zucman, N., Uhel, F., Descamps, D., Roux, D. & Ricard, J. D. Severe reinfection with South African SARS-CoV-2 variant 501Y.V2: A case report. *Clin Infect Dis*, doi:10.1093/cid/ciab129 (2021).

- 17 Romano, C. M. *et al.* SARS-CoV-2 reinfection caused by the P.1 lineage in Araraquara city, Sao Paulo State, Brazil. *Rev Inst Med Trop Sao Paulo* **63**, e36, doi:10.1590/S1678-9946202163036 (2021).
- 18 Goes, L. R. *et al.* New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil. *Infect Genet Evol* **94**, 104998, doi:10.1016/j.meegid.2021.104998 (2021).
- 19 Graham, M. S. *et al.* Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. *Lancet Public Health* **6**, e335-e345, doi:10.1016/S2468-2667(21)00055-4 (2021).
- 20 Amorim, M. R. *et al.* Respiratory Viral Shedding in Healthcare Workers Reinfected with SARS-CoV-2, Brazil, 2020. *Emerg Infect Dis* **27**, 1737-1740, doi:10.3201/eid2706.210558 (2021).
- 21 Camargo, C. H. *et al.* SARS-CoV-2 reinfection in a healthcare professional in inner Sao Paulo during the first wave of COVID-19 in Brazil. *Diagn Microbiol Infect Dis* **101**, 115516, doi:10.1016/j.diagmicrobio.2021.115516 (2021).
- 22 Fonseca, V. *et al.* Genomic evidence of SARS-CoV-2 reinfection case with the emerging B.1.2 variant in Brazil. *J Infect* **83**, 237-279, doi:10.1016/j.jinf.2021.05.014 (2021).
- 23 Nonaka, C. K. V. *et al.* Genomic Evidence of SARS-CoV-2 Reinfection Involving E484K Spike Mutation, Brazil. *Emerg Infect Dis* **27**, doi:10.3201/eid2705.210191 (2021).
- 24 Resende, P. C. *et al.* Severe Acute Respiratory Syndrome Coronavirus 2 P.2 Lineage Associated with Reinfection Case, Brazil, June-October 2020. *Emerg Infect Dis* **27**, 1789-1794, doi:10.3201/eid2707.210401 (2021).
- 25 Brazilian Ministry of Health Secretaria de Vigilância em Saúde. (eds Departamento de Imunização e Doenças Transmissíveis & Coordenação-Geral do Programa Nacional de Imunizações.) 4 (Brasília, DF, 2020).
- 26 Centers for Disease Control and Prevention. CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel. 80 (2020).
- 27 Biomanginhos FIOCRUZ. *Kit Molecular SARS-CoV-2 (informações e consulta de manuais)*, <<https://www.bio.fiocruz.br/index.php/br/produtos/reativos/testes-moleculares/novo-coronavirus-sars-cov2>> (2020).
- 28 Nascimento, V. A. D. *et al.* Genomic and phylogenetic characterisation of an imported case of SARS-CoV-2 in Amazonas State, Brazil. *Mem Inst Oswaldo Cruz* **115**, e200310, doi:10.1590/0074-02760200310 (2020).
- 29 Resende, P. *et al.* SARS-CoV-2 genomes recovered by long amplicon tiling multiplex approach using nanopore sequencing and applicable to other sequencing platforms. *bioRxiv* (2020). <<https://doi.org/10.1101/2020.04.30.069039>>.
- 30 Naveca, F. *et al.* Spread of Gamma (P.1) sub-lineages carrying Spike mutations close to the furin cleavage site and deletions in the N-terminal domain drives ongoing transmission of SARS-CoV-2 in Amazonas, Brazil. *medRxiv* (2021). <<https://www.medrxiv.org/content/10.1101/2021.09.12.21263453v1>>.
- 31 Li, W. & Godzik, A. Cd-hit: a fast program for clustering and comparing large sets of protein or nucleotide sequences. *Bioinformatics* **22**, 1658-1659, doi:10.1093/bioinformatics/btl158 (2006).
- 32 Katoh, K. & Standley, D. M. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. *Mol Biol Evol* **30**, 772-780, doi:10.1093/molbev/mst010 (2013).

- 33 Minh, B. Q. *et al.* IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era. *Mol Biol Evol* **37**, 1530-1534, doi:10.1093/molbev/msaa015 (2020).
- 34 Kalyaanamoorthy, S., Minh, B. Q., Wong, T. K. F., von Haeseler, A. & Jermin, L. S. ModelFinder: fast model selection for accurate phylogenetic estimates. *Nat Methods* **14**, 587-589, doi:10.1038/nmeth.4285 (2017).
- 35 Anisimova, M. & Gascuel, O. Approximate likelihood-ratio test for branches: A fast, accurate, and powerful alternative. *Syst Biol* **55**, 539-552, doi:10.1080/10635150600755453 (2006).
- 36 Deshpande, G. R. *et al.* Neutralizing antibody responses to SARS-CoV-2 in COVID-19 patients. *Indian J Med Res* **152**, 82-87, doi:10.4103/ijmr.IJMR_2382_20 (2020).
- 37 Feder, K. A. *et al.* Association of E484K spike protein mutation with SARS-CoV-2 infection in vaccinated persons---Maryland, January - May 2021. *Clin Infect Dis*, doi:10.1093/cid/ciab762 (2021).
- 38 Mostafa, H. H. *et al.* SARS-CoV-2 Infections in mRNA Vaccinated Individuals are Biased for Viruses Encoding Spike E484K and Associated with Reduced Infectious Virus Loads that Correlate with Respiratory Antiviral IgG levels. *medRxiv*, doi:10.1101/2021.07.05.21259105 (2021).
- 39 Servellita, V. *et al.* Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California. *medRxiv*, doi:10.1101/2021.08.19.21262139 (2021).
- 40 Dejnirattisai W *et al.* Antibody evasion by the P.1 strain of SARS-CoV-2. *Cell*, doi:10.1016/j.cell.2021.03.055 (2021).
- 41 Garcia-Beltran, W. F. *et al.* Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. *Cell*, doi:10.1016/j.cell.2021.03.013 (2021).
- 42 Hoffmann, M. *et al.* SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. *Cell*, doi:10.1016/j.cell.2021.03.036 (2021).
- 43 Caniels, T. G. *et al.* Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination. *medRxiv*, doi:10.1101/2021.05.26.21257441 (2021).
- 44 Wang, P. *et al.* Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization. *bioRxiv*, doi:10.1101/2021.03.01.433466 (2021).
- 45 Lucas, C. *et al.* Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. *Nature*, doi:10.1038/s41586-021-04085-y (2021).
- 46 Faria, N. R. *et al.* Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. *Science* **372**, 815-821, doi:10.1126/science.abh2644 (2021).
- 47 Naveca, F. G. *et al.* COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence. *Nat Med* **27**, 1230-1238, doi:10.1038/s41591-021-01378-7 (2021).
- 48 Anand, S. P. *et al.* Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset. *Cell Rep Med* **2**, 100290, doi:10.1016/j.xcrm.2021.100290 (2021).
- 49 Chia, W. N. *et al.* Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. *Lancet Microbe* **2**, e240-e249, doi:10.1016/S2666-5247(21)00025-2 (2021).
- 50 Cohen, K. W. *et al.* Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. *Cell Rep Med* **2**, 100354, doi:10.1016/j.xcrm.2021.100354 (2021).
- 51 Lumley, S. F. *et al.* The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in

- Individual Healthcare Workers. *Clin Infect Dis* **73**, e699-e709, doi:10.1093/cid/ciab004 (2021).
- 52 Townsend, J. P. *et al.* The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study. *Lancet Microbe*, doi:10.1016/S2666-5247(21)00219-6 (2021).
- 53 Singanayagam, A. *et al.* Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020. *Euro Surveill* **25**, doi:10.2807/1560-7917.ES.2020.25.32.2001483 (2020).
- 54 Jaafar, R. *et al.* Correlation between 3790 qPCR positives samples and positive cell cultures including 1941 SARS-CoV-2 isolates. *Clin Infect Dis*, doi:10.1093/cid/ciaa1491 (2020).
- 55 Cornelissen, L. & Andre, E. Understanding the drivers of transmission of SARS-CoV-2. *Lancet Infect Dis* **21**, 580-581, doi:10.1016/S1473-3099(21)00005-0 (2021).
- 56 Lee, L. Y. W. *et al.* SARS-CoV-2 infectivity by viral load, S gene variants and demographic factors and the utility of lateral flow devices to prevent transmission. *Clin Infect Dis*, doi:10.1093/cid/ciab421 (2021).
- 57 Selhorst, P. *et al.* Symptomatic SARS-CoV-2 reinfection of a health care worker in a Belgian nosocomial outbreak despite primary neutralizing antibody response. *Clin Infect Dis*, doi:10.1093/cid/ciaa1850 (2020).
- 58 Stamatatos, L. *et al.* mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. *Science*, doi:10.1126/science.abg9175 (2021).
- 59 Crotty, S. Hybrid immunity. *Science* **372**, 1392-1393, doi:10.1126/science.abj2258 (2021).
- 60 Schmidt, F. *et al.* High genetic barrier to escape from human polyclonal SARS-CoV-2 neutralizing antibodies. *bioRxiv* (2021).
<<https://doi.org/10.1101/2021.08.06.455491>>.
- 61 Khoury, D. S. *et al.* Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med* **27**, 1205-1211, doi:10.1038/s41591-021-01377-8 (2021).
- 62 Earle, K. A. *et al.* Evidence for antibody as a protective correlate for COVID-19 vaccines. *Vaccine* **39**, 4423-4428, doi:10.1016/j.vaccine.2021.05.063 (2021).
- 63 Feng, S. *et al.* Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. *Nat Med*, doi:10.1038/s41591-021-01540-1 (2021).
- 64 Lumley, S. F. *et al.* Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. *N Engl J Med*, doi:10.1056/NEJMoa2034545 (2020).
- 65 Krammer, F. A correlate of protection for SARS-CoV-2 vaccines is urgently needed. *Nat Med* **27**, 1147-1148, doi:10.1038/s41591-021-01432-4 (2021).
- 66 Liu, C. *et al.* Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. *Cell* **184**, 4220-4236 e4213, doi:10.1016/j.cell.2021.06.020 (2021).
- 67 Greaney, A. J. *et al.* A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy. *bioRxiv*, doi:10.1101/2021.10.12.464114 (2021).

Supplementary Figures

Figure S1: Epidemiological History of Gamma Reinfection Cases. The graph illustrates the epidemiological history of Gamma reinfection cases ($n = 25$), detailing its key events. When available, the onset of symptoms and sample collection for primo-infection and reinfection cases are represented in a timeline drawn for each individual. Sample collection events are accompanied by their observed real time PCR cycle threshold (Ct). Additionally, vaccination events are indicated. All time intervals are calculated from the onset of symptoms of the individual's primo-infection.

Figure S2. Phylogenetic and Molecular Characterization of Gamma Reinfection Cases.

The figure details the divergence observed between the SARS-CoV-2 genomes associated to each individual's primo-infection and reinfection cases. A. Cladogram-transformed Maximum likelihood (ML) tree ($n = 375$) of complete genomes (29,605 *nts*) from a selected group of variants identified in the outside blue archway. Primo-infection sequences ($n = 25$) are indicated by blue circles. The branch leading to the Gamma (P1 + P1*) variant is collapsed and colored in red. The tree was rooted using Wuhan reference sequence (EPI_ISL_402124). B. Cladogram-transformed ML tree of the Gamma variant subtree ($n = 172$) collapsed in A. Gamma variants are identified in the outside red archway. Reinfection cases ($n = 25$) are colored in red. Statistical support (SH-aLRT) of key nodes in A and B are indicated in the trees. C. Mapping of observed mutations in primo-infection (blue squares) and reinfection (red squares) genomes for all patients ($n = 25$).